News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

Kirk Hevener, PharmD, PhD

Advertisement

Articles by Kirk Hevener, PharmD, PhD

Study Shows Sulfonamide Antibacterials Capable of Reversing Azole Resistance in Candida albicans

ByKirk Hevener, PharmD, PhD
June 28th 2018

Preliminary studies provide convincing evidence for the synergistic use of sulfonamide agents with azole antifungals.

Advertisement

Latest Updated Articles

  • Study Shows Sulfonamide Antibacterials Capable of Reversing Azole Resistance in Candida albicans
    Study Shows Sulfonamide Antibacterials Capable of Reversing Azole Resistance in Candida albicans

    Published: June 28th 2018 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

CDC's Latest Hepatitis B Vaccine Guidance Serves as Example for Future Federal Vaccine Policy

2

Addressing the Three Pillars of PPE in Caring for Patients with High-Consequence Infectious Disease

3

Growing International Evidence Suggests Emerging Metallo-β-Lactamase Therapy Could Benefit US Clinicians

4

Vigilance, Training, and Funding are Key for Outbreak and Pandemic Biopreparedness

5

Top Infectious Disease News Stories Week of December 20 - December 26

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us